USE OF GENOMIC SIGNATURES TO PREDICT RESPONSIVENESS OF PATIENTS WITH PROSTATE CANCER TO POST-OPERATIVE RADIATION THERAPY

摘要

Methods, compositions, and kits for identifying individuals who will be responsive to post-operative radiation therapy for treatment of prostate cancer are disclosed. In particular, the invention relates to a genomic signature based on expression levels of DNA Damage Repair genes that can be used to identify individuals likely to benefit from post-operative radiation therapy after a prostatectomy.